Clinical Trial Update: Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma [Phase 3]

View source ↗

Summary

A Phase 3 multi-center trial evaluating Mipetresgene Autoleucel (Mip-cel) for NY-ESO-1 positive synovial sarcoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• Mipetresgene Autoleucel (Mip-cel) (Mipetresgene Autoleucel)

Snippet

Sponsor: Takara Bio Inc. | Conditions: Synovial Sarcomas | Phase 3 | Status: RECRUITING